Article

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies

2025-10-09

Abstract excerpt

<title>Abstract</title> <p>The serine/threonine kinase BRAF is frequently mutated in several tumor types, including melanoma and non-small cell lung cancer (NSCLC). Oncogenic BRAF mutations can be classified as Class I, II, or III owing to differences in underlying oncogenic mechanisms. While there are approved targeted therapies for BRAF Class I mutants, there are no approved targeted therapy strategies for Clas...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ee9cbd6c-371b-5979-a748-64b6e780ef40
DOI: 10.21203/rs.3.rs-5135027/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesDOI 10.21203/rs.3.rs-5135027/v1Read

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.Semantic proximity Read

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.Semantic proximity Read

Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.Semantic proximity Read

Drug resistance in targeted cancer therapies with RAF inhibitorsSemantic proximity Read

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.Semantic proximity Read

CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancersSemantic proximity Read

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.Semantic proximity Read

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLCSemantic proximity Read

The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition.Semantic proximity Read

RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read

613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumorsSemantic proximity Read

Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer.Semantic proximity Read